美国病理学家协会更新妇科癌生物标志物检测报告方案
CONTEXT.—: The first version of the Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin (hereafter referred to as the Gynecologic Biomarker Protocol) was released by the College of American Pathologists (CAP) in 2022…
要点
- 更新纳入PD-L1和叶酸受体α检测,并细化错配修复蛋白亚克隆缺失和p53亚克隆异常表达的报告。
- 激素受体和HER2检测推荐得到更新,所有解释性注释均修订以反映当前标准。
- 方案提供解释性注释和常见检测陷阱,帮助理解检测理由和结果解读。
核心结论
- 更新版CAP妇科癌生物标志物检测报告方案提升了预后和/或治疗标志物报告的结构与清晰度,并基于当前标准治疗提供全面注释。
研究设计与样本
- CAP癌症委员会组建妇科病理专家小组,基于现有证据和临床实践指南(如ASCO/CAP、NCCN、SITC)修订方案。
主要发现
- 方案更新包括激素受体检测、新增错配修复蛋白亚克隆缺失、p53亚克隆异常表达、PD-L1检测和叶酸受体α检测,以及HER2检测更新和全部注释修订。
临床怎么用
- 病理科医生可依据更新方案规范报告妇科癌生物标志物检测结果,并参考注释理解检测理由、结果解读和常见陷阱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: The first version of the Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin (hereafter referred to as the Gynecologic Biomarker Protocol) was released by the College of American Pathologists (CAP) in 2022. Minor updates included clarification of the content of p53 status and explanatory notes for human epidermal growth factor receptor 2 (HER2) and mismatch repair testing in 2023. Recent developments in biomarker testing have prompted a major update to this protocol, published in December 2024. OBJECTIVE.—: To assess prognostic and/or therapeutic markers since the release of the 2023 Gynecologic Biomarker Protocol and to update testing recommendations in gynecologic carcinomas, with expanded explanatory notes and illustrative examples provided in this article. DESIGN.—: The CAP Cancer Committee assembled a panel of experts subspecialized in gynecologic pathology to augment the existing biomarkers, add new biomarkers, expand test reporting, and revise explanatory notes based on available evidence and clinical practice guidelines such as those of the American Society of Clinical Oncology/CAP, National Comprehensive Cancer Network, and Society for Immunotherapy of Cancer. RESULTS.—: The changes to the Gynecologic Biomarker Protocol include updates to hormone receptors and addition of subclonal loss of mismatch repair proteins, subclonal abnormal p53 expression, programmed death ligand-1 (PD-L1) testing, and folate receptor alpha testing, as well as updates to HER2 testing and all explanatory notes. CONCLUSIONS.—: The updated CAP Gynecologic Biomarker Protocol provides improved structure and clarity in the reporting of prognostic and/or therapeutic biomarkers and comprehensive explanatory notes that aid in understanding the rationale for testing, interpretive guidance, and common testing pitfalls, based on the current standard of care.
引用
- Turashvili G, Karnezis AN, Hulkower KI, et al. Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin: The Updated College of American Pathologists Protocol. Arch Pathol Lab Med. 2025. PMID: 40956279. doi:10.5858/arpa.2025-0157-CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。